13Q deletion in predominant cytogenetic aberration newly aquired during chronic lymohocytic leukemia course irrespective of disease activity and treatment status.

KOTAŠKOVÁ, Jana, Jitka MALČÍKOVÁ, Eva DIVÍŠKOVÁ, Šárka PAVLOVÁ, Soňa MEJSTŘÍKOVÁ, V. VRÁNOVÁ, Karla PLEVOVÁ, Hana PLEŠINGEROVÁ, Michael DOUBEK, Jiří MAYER and Šárka POSPÍŠILOVÁ. 13Q deletion in predominant cytogenetic aberration newly aquired during chronic lymohocytic leukemia course irrespective of disease activity and treatment status. In 20th Congress of the European Hematology Association in Haematologica. 2015.

Basic information

• Original name: 13Q deletion in predominant cytogenetic aberration newly aquired during chronic lymohocytic leukemia course irrespective of disease activity and treatment status.
• Name (in English): 13Q deletion in predominant cytogenetic aberration newly aquired during chronic lymohocytic leukemia course irrespective of disease activity and treatment status.
• Authors: KOTAŠKOVÁ, Jana, Jitka MALČÍKOVÁ, Eva DIVÍŠKOVÁ, Šárka PAVLOVÁ, Soňa MEJSTŘÍKOVÁ, V. VRÁNOVÁ, Karla PLEVOVÁ, Hana PLEŠINGEROVÁ, Michael DOUBEK, Jiří MAYER and Šárka POSPÍŠILOVÁ.
• Edition: 20th Congress of the European Hematology Association in Haematologica, 2015.

Other information

• Type of outcome: Conference abstract
• Field of Study: 30200 3.2 Clinical medicine
• Confidentiality degree: is not subject to a state or trade secret
• Organization unit: Central European Institute of Technology
• Tags: International impact, Reviewed

Links

• ED1.1.00/02.0068, research and development project: Name: CEITEC - central european institute of technology
• NT13493, research and development project: Name: Molekulární charakterizace B buněčných receptorů a jejich vztah k evoluci genetických změn u chronické lymfocytární leukémie
• NT13519, research and development project: Name: Časná identifikace CLL pacientů s dosud nevyselektovanými mutacemi v proteinu p53
• 306242, interní kód MU: Name: NGS-PTL - Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia (Acronym: NGS-PTL)

Investor: European Union, Cooperation

• 7E13008, research and development project: Name: Next Generation Sequencing Platform for Targeted Personalized Therapy of Leukemia (Acronym: NGS-PTL)

Investor: Ministry of Education, Youth and Sports of the CR